Nurix Therapeutics, Inc.
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Last report0 of 8 at or beyond impliedshaded = implied▲▼ = realized× = |realized| ÷ implied
−0.14%
vs ±17.9% implied · ×0.01
shaded = implied · ▲▼ = realized
Nurix Therapeutics has 1 disclosed supplier and 6 disclosed customers in SEC filings.
Nurix Therapeutics, Inc.
26.85
SentenceFor example, in March 2023, Silicon Valley Bank (SVB), which was one of our banking partners, was closed by the California Department of Financial Protection and Innovation, which appointed the Federal Deposit Insurance Corporation (FDIC) as receiver, and in March 2023, Silvergate Capital Corp. and Signature Bank were similarly swept into receivership.
NRIX 10-Kaccession 0001549595-26-000016
SentenceUnder the terms of the Pfizer Agreement, we received an upfront payment of $60.0 million.
SentenceIn December 2019, we entered into a strategic collaboration with Genzyme Corporation, a subsidiary of Sanofi, which became effective in January 2020 (as subsequently expanded and amended, the Sanofi Agreement), to discover, develop and commercialize a pipeline of targeted protein degradation drugs for patients with challenging diseases in multiple therapeutic areas using our DEL-AI platform to identify small molecules designed to induce degradation of three specified initial drug targets.
NRIX 10-Kaccession 0001549595-26-000016
SentenceIn September 2023, we entered into a strategic collaboration with Seagen Inc. (now a part of Pfizer Inc.) (the Pfizer Agreement) to develop a suite of targeted protein degraders against multiple targets nominated by Pfizer that are suitable for antibody conjugation.
NRIX 10-Kaccession 0001549595-26-000016
Linked news
Expected move
No implied move.